NeoVax

NeoVax is a personalized experimental vaccine designed to recognize cancer-specific proteins, called neoantigens, that are present on the individual’s cancer cells but not on normal cells.

The vaccine, known as NeoVax, is based on research at Dana-Farber led by Catherine Wu, M.D.  

David Braun, MD, Ph.D. said that such a vaccine could “steer” the immune response – after being freed by the checkpoint blocker drug – to focus tightly on the cancer cells.

A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma is not yet recruiting patients.